{"gene":"IP6K2","run_date":"2026-04-28T18:06:54","timeline":{"discoveries":[{"year":2001,"finding":"IP6K2 (RID-2) is post-transcriptionally induced by IFN-beta in ovarian carcinoma cells and mediates IFN-beta-induced apoptosis; a mutant IP6K2 with substitutions in the putative inositol phosphate binding domain abrogates IFN-beta-induced apoptosis, establishing its kinase activity as required for this function.","method":"Antisense technical knockout, kinase-dead mutant expression, apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function with specific phenotypic readout plus mutagenesis of catalytic domain, replicated in multiple follow-up studies","pmids":["11337497"],"is_preprint":false},{"year":2002,"finding":"IP6K2 overexpression sensitizes ovarian carcinoma cells to IFN-beta and gamma-irradiation-induced apoptosis by enhancing caspase-8 expression and functioning through DR4/DR5-mediated extrinsic apoptotic pathway; Bcl-2 and dominant-negative DR5 block these effects.","method":"Overexpression, colony forming assay, caspase-8 mRNA induction, dominant-negative mutant DR5 and Bcl-2 blocking","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — clean overexpression with defined pathway placement, single lab","pmids":["11896621"],"is_preprint":false},{"year":2005,"finding":"IP6K2 undergoes nuclear translocation after IFN-beta treatment, and this nuclear localization is required for IFN-beta-induced apoptosis; mutations in the NLS of IP6K2 trap the protein in the cytoplasm and confer resistance to IFN-beta-induced cell death.","method":"IP6K2-eGFP fusion live imaging, NLS point mutant expression, apoptosis assays","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 — direct localization experiment with functional consequence via mutagenesis, moderate evidence","pmids":["15634191"],"is_preprint":false},{"year":2007,"finding":"IP6K2 binds TRAF2 via residues Ser-347 and Ser-359, thereby interfering with phosphorylation of TAK1 and inhibiting NF-kappaB signaling; S347A/S359A mutations abolish TRAF2 binding and lead to enhanced TAK1 and NF-kappaB activation following TNF-alpha stimulation.","method":"Co-immunoprecipitation, site-directed mutagenesis, TAK1 phosphorylation assay, NF-kappaB DNA binding assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal interaction with mutagenesis and defined pathway placement","pmids":["17379600"],"is_preprint":false},{"year":2008,"finding":"HSP90 physically binds IP6K2 and inhibits its catalytic activity; disruption of this interaction (by HSP90 inhibitory drugs or selective mutations) activates IP6K2 and leads to cell death, identifying HSP90 as a physiological negative regulator of IP6K2.","method":"Co-immunoprecipitation, in vitro kinase assay, mutagenesis, pharmacological HSP90 inhibition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal Co-IP plus in vitro catalytic assay plus mutagenesis in single study","pmids":["18195352"],"is_preprint":false},{"year":2009,"finding":"IP6K2 knockout mice show increased susceptibility to carcinogen-induced oral/esophageal squamous cell carcinoma and paradoxical resistance to ionizing radiation with accelerated DNA repair; direct microinjection of the IP6K2 product 5-PP-Ins(1,2,3,4,6)P5 (but not the substrate IP6) induces cell death, confirming the product mediates apoptosis.","method":"Targeted gene knockout mice, carcinogen treatment, comet assay, direct microinjection of inositol pyrophosphate","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 — KO mouse with defined phenotypes and direct product injection experiment","pmids":["19430495"],"is_preprint":false},{"year":2010,"finding":"IP6K2 is required for p53-mediated apoptosis: gene disruption of IP6K2 in colorectal cancer cells selectively impairs p53-mediated apoptosis (favoring cell-cycle arrest instead), and IP6K2 binds directly to p53, decreasing expression of pro-arrest targets such as p21.","method":"Gene disruption (KO), p53 apoptosis assays, direct co-immunoprecipitation of IP6K2 with p53, p21 expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — KO with defined apoptosis/arrest phenotype plus direct IP6K2-p53 binding shown by Co-IP","pmids":["21078964"],"is_preprint":false},{"year":2010,"finding":"IP6K2 activity in zebrafish is required for normal craniofacial, somite, and neural crest development and acts as a positive regulator of the Hedgehog signaling pathway downstream of or at the level of Smoothened but upstream of the transcription factor Gli1.","method":"Morpholino knockdown in zebrafish, pharmacological IP6K inhibition (TNP), genetic epistasis with smoM2/gli1/ip6k2 overexpression, reversal of cyclopamine inhibition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in zebrafish with multiple rescue/override experiments placing IP6K2 in Hh pathway","pmids":["20980661"],"is_preprint":false},{"year":2011,"finding":"Casein kinase-2 (CK2) promotes cell survival by phosphorylating IP6K2 at Ser-347 and Ser-356 within a PEST sequence, leading to IP6K2 ubiquitination and proteasomal degradation; CK2-resistant IP6K2 mutants at these sites are metabolically stable, and cells depleted of IP6K2 are resistant to CK2 inhibitor-induced cell death.","method":"In vitro phosphorylation assay, site-directed mutagenesis, ubiquitination assay, metabolic stability assay, CK2 inhibitor treatment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — in vitro phosphorylation plus mutagenesis plus ubiquitination assay in single study","pmids":["21262846"],"is_preprint":false},{"year":2014,"finding":"IP7 generated by IP6K2 binds CK2 to enhance CK2 phosphorylation of the TTT cochaperone complex (Tel2/Tti1/Tti2), thereby stabilizing DNA-PKcs and ATM, which then phosphorylate p53 at Ser-15 to activate the apoptotic program in cancer cells and murine B cells.","method":"In vitro CK2 kinase assay with IP7, binding assays, co-immunoprecipitation, cell-based apoptosis assays with IP6K2 modulation","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 — reconstituted biochemical cascade with in vitro kinase assay plus cell-based epistasis, published in high-impact journal","pmids":["24657168"],"is_preprint":false},{"year":2014,"finding":"Crystal structure of an Entamoeba histolytica hybrid IP6K/IP3K was solved and used with molecular modelling and mutagenesis to define the substrate-binding pocket of human IP6K2; two structural elements (an α-helical pair and a 310 helix) form an open clamshell geometry that accommodates InsP6; human IP6K2 retains vestigial IP3K activity.","method":"X-ray crystallography, molecular modelling, site-directed mutagenesis, kinase activity assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus mutagenesis and functional assay in single study","pmids":["24956979"],"is_preprint":false},{"year":2015,"finding":"IP6K2, via IP7 synthesis, promotes cancer cell migration and tumor metastasis by enhancing cell-matrix adhesion and decreasing cell-cell adhesion; this is mediated by IP7-elicited nuclear sequestration and inactivation of the tumor suppressor LKB1.","method":"Cell migration/invasion assays, IP6K2 knockdown, IP7 measurement, subcellular fractionation, LKB1 localization and activity assays, in vivo metastasis mouse model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal assays (cell culture + in vivo) placing IP6K2/IP7 upstream of LKB1 nuclear inactivation","pmids":["25617365"],"is_preprint":false},{"year":2018,"finding":"IP6K2 binds protein 4.1N with high affinity and specificity; nuclear translocation of 4.1N is dependent on IP6K2; both proteins are highly expressed in cerebellar granule cells and their interaction regulates Purkinje cell morphology, cerebellar synapses, and locomotor function; disruption of IP6K2-4.1N interaction impairs cell viability.","method":"Co-immunoprecipitation, IP6K2 knockout mice, immunofluorescence, synaptic morphology analysis, locomotor behavioral tests","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP plus KO mouse phenotype plus localization-function link","pmids":["30006360"],"is_preprint":false},{"year":2019,"finding":"IP6K1 and IP6K2 together control inositol pyrophosphate (IP7 and IP8) metabolism and thereby regulate phosphate export through the XPR1 phosphate exporter, whose SPX domain is bound by inositol pyrophosphates; double KO of IP6K1/2 in HCT116 cells elevates intracellular phosphate and alters phosphate flux.","method":"CRISPR knockout of IP6K1/2, PAGE and HPLC inositol phosphate profiling, nucleotide analysis, Malachite green phosphate assay, [32Pi] pulse labeling, XPR1 SPX domain binding assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — genetic KO plus multiple biochemical assays demonstrating IP7/IP8 depletion and XPR1 binding","pmids":["31186349"],"is_preprint":false},{"year":2021,"finding":"IP6K2 associates with creatine kinase-B (CK-B) in mouse brain; IP6K2-KO cerebella show reduced phosphocreatine and ATP, increased reactive oxygen species, increased protein oxidative damage, and impaired cytochrome-c1 (complex III) expression, establishing IP6K2-CK-B interaction as a regulator of energy homeostasis and neuroprotection.","method":"Proteomic interactome (IP6K2 pull-down/MS), co-immunoprecipitation, metabolite assays (phosphocreatine, ATP, ROS), IP6K2 knockout mice, rescue with N-acetylcysteine and phosphocreatine","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — MS-identified binding partner confirmed by Co-IP, KO phenotype with biochemical readouts and partial rescue","pmids":["33547244"],"is_preprint":false},{"year":2022,"finding":"IP6K2 attenuates PINK1-mediated mitophagy in the brain through a catalytically independent mechanism; overexpression of both wild-type and kinase-dead IP6K2 reverses mitophagy markers in knockdown cells; the mitoprotective effect of IP6K2 depends on PINK1, as IP6K2 supplementation fails to reverse LC3-II in IP6K2-PINK1 double-knockdown cells.","method":"IP6K2 knockdown, kinase-dead mutant overexpression, PINK1 double knockdown, Western blot for mitophagy/mitochondrial markers (Drp-1, PGC1-α, NRF-1, LC3-II)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — kinase-dead mutant distinguishes catalytic vs. non-catalytic function; epistasis with PINK1 double-KD","pmids":["35353626"],"is_preprint":false},{"year":2023,"finding":"IP6K2-generated 5-IP7 modulates nucleolar granular region architecture: overexpression of wild-type (but not kinase-dead) IP6K2 expands the outer nucleolar granular region, while IP6K1+IP6K2 siRNA knockdown or pan-IP6K inhibition shrinks it back; proposed mechanism is electrostatic bridging of positively charged nucleolar protein surfaces.","method":"Quantitative confocal imaging, CRISPR-KO (NUDT3, PPIP5Ks), wild-type vs. kinase-dead IP6K2 expression, siRNA knockdown, pan-IP6K inhibitor","journal":"Biomolecules","confidence":"Medium","confidence_rationale":"Tier 2 — direct imaging with kinase-dead control, single lab, mechanistic model proposed but not biochemically reconstituted","pmids":["36671538"],"is_preprint":false},{"year":2023,"finding":"IP6K2 expression in enteric neurons drives high IP7 synthesis in the gastrointestinal tract; IP6K2-knockout mice show significantly impaired IP7 metabolism in the gut, and transcriptome analysis of duodenal muscularis externa indicates the IP6K2-IP7 axis regulates genes associated with neuronal differentiation, maturation, and function of the enteric nervous system.","method":"LC-MS inositol pyrophosphate profiling, IP6K2-KO mice, tissue fractionation, whole transcriptome analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse with LC-MS quantification and transcriptome, but downstream mechanism not fully reconstituted","pmids":["36681123"],"is_preprint":false},{"year":2025,"finding":"IP6K2-generated 5-IP7 promotes E-cadherin endocytosis in colorectal cancer by inhibiting inositol 5-phosphatases (e.g., OCRL), thereby elevating PI(4,5)P2 levels at adherens junctions and recruiting endocytic adaptors; IP6K2 is activated via a ROS-Src phosphorylation axis; intestinal epithelium-specific IP6K2 deletion attenuates DSS-induced colitis/CRC.","method":"In vitro kinase assay, Co-IP, PI(4,5)P2 measurement, endocytosis assays, OCRL binding-deficient mutant, IP6K2 conditional KO mice, DSS colitis model, IP6K2-selective inhibitor","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal biochemical assays (kinase assay, PI(4,5)P2 measurement, binding mutant, KO mouse, selective inhibitor) establishing mechanistic cascade","pmids":["40858937"],"is_preprint":false},{"year":2024,"finding":"IP6K2 (together with IP6K1) is required for synthesis of renal 5-IP7 and for normal expression and function of proximal tubule Na+/Pi cotransporters NaPi-IIa and NaPi-IIc; renal tubule-specific Ip6k1/2-KO mice develop hypophosphatemia, reduced FGF23, increased bone resorption, diuresis, albuminuria, and hypercalciuria.","method":"Renal cell line (opossum kidney) IP6K knockdown, renal tubular-specific Ip6k1/2-KO mice, phosphate transport assays, brush border membrane vesicle uptake, plasma metabolite measurements","journal":"Journal of the American Society of Nephrology","confidence":"High","confidence_rationale":"Tier 2 — conditional KO mouse with multiple biochemical and physiological phenotypic readouts","pmids":["38317282"],"is_preprint":false},{"year":2023,"finding":"A gatekeeper mutation in IP6K2 (valine substitution) sensitizes it to an allosteric inhibitor (FMP-201300) that binds an allosteric pocket adjacent to the ATP-binding site by displacing the αC helix; hydrogen-deuterium exchange mass spectrometry confirmed the allosteric mechanism.","method":"Analog-sensitive kinase approach, high-throughput screen, HDX-MS, biochemical kinase inhibition assays","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 1 — HDX-MS structural evidence plus biochemical validation, single study","pmids":["37843983"],"is_preprint":false},{"year":2026,"finding":"IP6K2 silencing in calcifying vascular smooth muscle cells (VSMCs) ameliorates phosphate-induced pro-calcific marker expression and VSMC calcification; mechanistically, IP6K2-produced 5-IP7 inhibits AKT signaling, and AKT inhibition abolishes the protective effects of IP6K2 knockdown while SGK1 inhibition restores them, suggesting an IP6K2/5-IP7-AKT/SGK1 signaling axis in calcification.","method":"IP6K2 siRNA knockdown in primary human aortic VSMCs, calcification assays, AKT phosphorylation Western blot, AKT and SGK1 inhibitors","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — clean KD with pharmacological rescue placing IP6K2 upstream of AKT/SGK1, single lab","pmids":["41683831"],"is_preprint":false}],"current_model":"IP6K2 is an inositol hexakisphosphate kinase that generates the inositol pyrophosphate 5-IP7 (diphosphoinositol pentakisphosphate); it promotes apoptosis by directly binding p53 and modulating its transcriptional output, activates CK2-mediated phosphorylation of the TTT cochaperone complex to stabilize DNA-PKcs/ATM and drive p53 Ser-15 phosphorylation, inhibits NF-κB signaling by binding TRAF2 and blocking TAK1 phosphorylation, undergoes IFN-beta-induced nuclear translocation required for apoptosis, is kept in check by HSP90 binding (which inhibits its catalytic activity) and by CK2-mediated PEST-site phosphorylation that targets it for ubiquitin-proteasomal degradation; 5-IP7 also acts as a positive effector of Hedgehog signaling (downstream of Smoothened, upstream of Gli1), promotes LKB1 nuclear inactivation to drive tumor metastasis, inhibits OCRL phosphatase at adherens junctions to elevate PI(4,5)P2 and license E-cadherin endocytosis, and regulates phosphate homeostasis (via XPR1 and renal NaPi-IIa/IIc), mitochondrial energy dynamics through CK-B interaction, and PINK1-dependent mitophagy through a non-catalytic mechanism."},"narrative":{"teleology":[{"year":2001,"claim":"Establishing IP6K2 as a pro-apoptotic kinase answered whether inositol pyrophosphate metabolism was linked to programmed cell death: IFN-β post-transcriptionally induces IP6K2, and its catalytic activity is required for IFN-β-induced apoptosis.","evidence":"Antisense knockdown and kinase-dead mutant expression in ovarian carcinoma cells with apoptosis readouts","pmids":["11337497"],"confidence":"High","gaps":["Downstream mediators of IP6K2-driven apoptosis were unknown","Whether 5-IP7 itself or another product mediated the effect was unresolved"]},{"year":2002,"claim":"Identifying the extrinsic death receptor pathway as a downstream effector placed IP6K2 upstream of DR4/DR5 and caspase-8 in apoptosis signaling.","evidence":"Overexpression in ovarian carcinoma cells; blocking by dominant-negative DR5 and Bcl-2","pmids":["11896621"],"confidence":"Medium","gaps":["Reliance on overexpression without loss-of-function confirmation","Whether endogenous IP6K2 levels are sufficient to engage DR4/DR5 was untested"]},{"year":2005,"claim":"Demonstrating IFN-β-induced nuclear translocation of IP6K2 and its requirement for apoptosis resolved where in the cell IP6K2 must act to execute its death-promoting function.","evidence":"IP6K2-eGFP fusion imaging and NLS point mutant expression in apoptosis assays","pmids":["15634191"],"confidence":"High","gaps":["Nuclear substrates or binding partners mediating apoptosis were unidentified","Whether catalysis occurs in the nucleus or whether nuclear localization serves a scaffolding role was unclear"]},{"year":2007,"claim":"Discovery that IP6K2 binds TRAF2 and inhibits TAK1/NF-κB signaling revealed a second mechanism through which IP6K2 shifts cell fate toward apoptosis — by suppressing pro-survival NF-κB.","evidence":"Co-immunoprecipitation, S347A/S359A mutagenesis, TAK1 phosphorylation and NF-κB DNA binding assays","pmids":["17379600"],"confidence":"High","gaps":["Whether this requires catalytic activity or is a scaffolding function was not dissected","In vivo relevance of the TRAF2 interaction was not tested"]},{"year":2008,"claim":"Identifying HSP90 as a physical inhibitor of IP6K2 catalytic activity established a tonic brake on IP6K2 and explained how HSP90 inhibitors trigger cell death — by unleashing IP6K2.","evidence":"Reciprocal Co-IP, in vitro kinase assay, HSP90 inhibitor treatment, mutagenesis","pmids":["18195352"],"confidence":"High","gaps":["Whether HSP90 regulates IP6K2 stability in addition to activity was unresolved","Structural basis of HSP90-IP6K2 interaction was unknown"]},{"year":2009,"claim":"IP6K2 knockout mice provided in vivo confirmation that IP6K2 is a tumor suppressor: KO animals show increased carcinogen susceptibility, and direct microinjection of 5-IP7 induces cell death, proving the product — not the enzyme per se — mediates apoptosis.","evidence":"IP6K2 knockout mice, carcinogen-induced tumor model, microinjection of 5-PP-InsP5","pmids":["19430495"],"confidence":"High","gaps":["The paradoxical radiation resistance and accelerated DNA repair in KO mice remained mechanistically unexplained","Whether compensatory IP6K1/3 activity confounds phenotypes was not addressed"]},{"year":2010,"claim":"Two advances linked IP6K2 to specific signaling pathways: direct binding to p53 shifts its transcriptional output from arrest to apoptosis, and genetic epistasis in zebrafish placed IP6K2 downstream of Smoothened in Hedgehog signaling.","evidence":"IP6K2 KO in HCT116 cells with p53 apoptosis/arrest readouts and Co-IP (p53); morpholino knockdown in zebrafish with Hh pathway epistasis (Hedgehog)","pmids":["21078964","20980661"],"confidence":"High","gaps":["How IP6K2 binding alters p53 target gene selectivity at the chromatin level was unknown","The Hedgehog mechanism lacked identification of a direct IP6K2/IP7 target between Smoothened and Gli1"]},{"year":2011,"claim":"CK2-mediated phosphorylation of IP6K2 PEST residues triggers its ubiquitination and proteasomal degradation, revealing a feedback loop: CK2 activity promotes survival by eliminating the pro-apoptotic kinase.","evidence":"In vitro CK2 phosphorylation, mutagenesis of Ser-347/Ser-356, ubiquitination assay, metabolic stability","pmids":["21262846"],"confidence":"High","gaps":["The specific E3 ubiquitin ligase was not identified","Whether CK2-mediated degradation is stimulus-regulated was untested"]},{"year":2014,"claim":"Reconstitution of a 5-IP7→CK2→TTT→DNA-PKcs/ATM→p53-Ser15 cascade provided the first complete biochemical pathway from IP6K2 catalytic product to p53 activation, while structural analysis revealed the substrate-binding clamshell geometry of the IP6K family.","evidence":"In vitro CK2 kinase assay with IP7, Co-IP, cell-based epistasis (signaling cascade); X-ray crystallography of Entamoeba IP6K, human IP6K2 modeling and mutagenesis (structure)","pmids":["24657168","24956979"],"confidence":"High","gaps":["A high-resolution structure of human IP6K2 itself was still lacking","Whether CK2 activation by IP7 is selective to IP6K2-derived pools vs. IP6K1-derived pools was not resolved"]},{"year":2015,"claim":"Demonstrating that IP6K2/IP7 promotes tumor metastasis via nuclear sequestration and inactivation of LKB1 revealed a pro-tumorigenic face of IP6K2, contrasting its well-established tumor-suppressive apoptotic role.","evidence":"Cell migration/invasion assays, IP6K2 knockdown, LKB1 localization, in vivo metastasis model","pmids":["25617365"],"confidence":"High","gaps":["How 5-IP7 mechanistically drives LKB1 nuclear sequestration was not biochemically defined","Context-dependent switching between tumor-suppressive and pro-metastatic roles was unexplained"]},{"year":2018,"claim":"Identification of protein 4.1N as a high-affinity IP6K2 partner linked IP6K2 to cerebellar function: IP6K2 controls 4.1N nuclear translocation, and their interaction regulates Purkinje cell morphology and locomotor behavior.","evidence":"Reciprocal Co-IP, IP6K2 KO mice, cerebellar immunofluorescence, locomotor behavioral tests","pmids":["30006360"],"confidence":"High","gaps":["Whether the 4.1N interaction requires IP6K2 catalytic activity was not tested","Downstream nuclear targets of 4.1N were unknown"]},{"year":2019,"claim":"Demonstrating that IP6K1/2-generated inositol pyrophosphates bind the SPX domain of XPR1 and control phosphate export established IP6K2 as a regulator of cellular phosphate homeostasis.","evidence":"CRISPR double KO of IP6K1/2 in HCT116, HPLC/PAGE IP7/IP8 profiling, 32Pi flux, SPX domain binding assay","pmids":["31186349"],"confidence":"High","gaps":["Individual contributions of IP6K1 vs. IP6K2 to XPR1 regulation were not separated","In vivo phosphate phenotypes of IP6K2-single KO were not reported in this study"]},{"year":2021,"claim":"Discovery that IP6K2 associates with creatine kinase-B and that IP6K2 KO cerebella show depleted phosphocreatine/ATP and elevated ROS established a bioenergetic function for IP6K2 in neuroprotection.","evidence":"Proteomic pull-down/MS, Co-IP, metabolite quantification, IP6K2 KO mice, rescue with N-acetylcysteine and phosphocreatine","pmids":["33547244"],"confidence":"High","gaps":["Whether IP6K2 enzymatic activity or a scaffolding role underlies the CK-B interaction was unresolved","Mechanism linking IP6K2-CK-B to cytochrome c1/complex III expression was unclear"]},{"year":2022,"claim":"Demonstrating that both wild-type and kinase-dead IP6K2 attenuate PINK1-dependent mitophagy in a PINK1-epistatic manner uncovered a catalytically independent, non-canonical function of IP6K2 in mitochondrial quality control.","evidence":"IP6K2 knockdown and kinase-dead rescue, PINK1 double-KD epistasis, mitophagy marker Western blots","pmids":["35353626"],"confidence":"High","gaps":["Direct physical interaction between IP6K2 and PINK1 was not shown","Whether the non-catalytic mechanism involves a scaffolding surface or protein-protein interaction domain was undetermined"]},{"year":2023,"claim":"Multiple studies expanded IP6K2's tissue-specific roles: IP6K2 is the dominant IP7 source in enteric neurons and regulates enteric nervous system gene programs; IP6K2-derived IP7 modulates nucleolar granular region architecture; and an allosteric inhibitor pocket was mapped by HDX-MS.","evidence":"IP6K2-KO mice with gut LC-MS IP7 profiling and transcriptomics (enteric); confocal imaging with WT vs. kinase-dead IP6K2 (nucleolus); analog-sensitive kinase screen with HDX-MS (allosteric pocket)","pmids":["36681123","36671538","37843983"],"confidence":"Medium","gaps":["Enteric neuron phenotypes were transcriptomic without functional neuronal assays","Nucleolar mechanism proposed as electrostatic bridging but not biochemically reconstituted","Allosteric inhibitor tested only on gatekeeper mutant, not wild-type IP6K2"]},{"year":2024,"claim":"Renal tubular-specific IP6K1/2 knockout revealed that IP6K2-derived 5-IP7 is essential for NaPi-IIa/IIc expression and renal phosphate reabsorption, with KO mice developing hypophosphatemia and secondary bone/mineral phenotypes.","evidence":"Conditional renal tubular Ip6k1/2-KO mice, brush border membrane vesicle phosphate uptake, plasma metabolite measurements","pmids":["38317282"],"confidence":"High","gaps":["Individual contribution of IP6K2 vs. IP6K1 in the renal tubule was not dissected","Mechanism by which 5-IP7 regulates NaPi-IIa/IIc expression (transcriptional vs. post-translational) was not defined"]},{"year":2025,"claim":"A ROS→Src→IP6K2→5-IP7⊣OCRL→PI(4,5)P2→E-cadherin endocytosis axis was delineated in colorectal cancer, and intestinal epithelium-specific IP6K2 deletion attenuated colitis-associated carcinogenesis, establishing IP6K2 as a druggable node in junction remodeling.","evidence":"In vitro kinase assay, OCRL binding-deficient mutant, PI(4,5)P2 measurement, conditional KO mice in DSS colitis model, IP6K2-selective inhibitor","pmids":["40858937"],"confidence":"High","gaps":["Whether OCRL inhibition by 5-IP7 is direct or mediated by an intermediate was not fully resolved","Specificity of the IP6K2-selective inhibitor in vivo was not comprehensively profiled"]},{"year":null,"claim":"Key unresolved questions include: the high-resolution structure of human IP6K2, how IP6K2 switches between tumor-suppressive and pro-metastatic outputs in different cellular contexts, the identity of the E3 ligase mediating CK2-dependent IP6K2 degradation, and how IP6K2's catalytic and non-catalytic functions are coordinately regulated.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No crystal structure of full-length human IP6K2","E3 ubiquitin ligase for IP6K2 degradation unidentified","Context-dependent switch between pro-apoptotic and pro-metastatic roles is mechanistically unexplained"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,5,9,10,13,18]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,6,15,18]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,12,16]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,4]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[16]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,1,5,6,9]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,7,9,11,21]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[13,14,19]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[13,19]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[15]}],"complexes":[],"partners":["TP53","TRAF2","HSP90","EPB41L1","CKB","CSNK2A1","OCRL","PINK1"],"other_free_text":[]},"mechanistic_narrative":"IP6K2 is an inositol hexakisphosphate kinase that generates 5-PP-InsP5 (5-IP7), a signaling pyrophosphate that controls cell-fate decisions spanning apoptosis, proliferation, phosphate homeostasis, and tissue morphogenesis. IP6K2 promotes apoptosis through multiple convergent mechanisms: its product 5-IP7 activates CK2-dependent phosphorylation of the TTT cochaperone complex to stabilize DNA-PKcs/ATM and drive p53 Ser-15 phosphorylation [PMID:24657168]; IP6K2 directly binds p53 to shift transcriptional output from cell-cycle arrest toward apoptosis [PMID:21078964]; and it inhibits NF-κB survival signaling by binding TRAF2 and blocking TAK1 phosphorylation [PMID:17379600]. Beyond apoptosis, IP6K2 acts as a positive regulator of Hedgehog signaling downstream of Smoothened [PMID:20980661], controls phosphate export via XPR1 and renal NaPi-IIa/IIc cotransporter expression [PMID:31186349, PMID:38317282], promotes E-cadherin endocytosis by inhibiting OCRL to elevate PI(4,5)P2 at adherens junctions [PMID:40858937], and regulates mitochondrial energy homeostasis through its interaction with creatine kinase-B and a catalytically independent attenuation of PINK1-mediated mitophagy [PMID:33547244, PMID:35353626]."},"prefetch_data":{"uniprot":{"accession":"Q9UHH9","full_name":"Inositol hexakisphosphate kinase 2","aliases":["P(i)-uptake stimulator","PiUS"],"length_aa":426,"mass_kda":49.2,"function":"Converts inositol hexakisphosphate (InsP6) to diphosphoinositol pentakisphosphate (InsP7/PP-InsP5)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9UHH9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IP6K2","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IP6K2","total_profiled":1310},"omim":[{"mim_id":"606993","title":"INOSITOL HEXAPHOSPHATE KINASE 3; IP6K3","url":"https://www.omim.org/entry/606993"},{"mim_id":"606992","title":"INOSITOL HEXAPHOSPHATE KINASE 2; IP6K2","url":"https://www.omim.org/entry/606992"},{"mim_id":"606991","title":"INOSITOL HEXAPHOSPHATE KINASE 1; IP6K1","url":"https://www.omim.org/entry/606991"},{"mim_id":"140571","title":"HEAT-SHOCK PROTEIN, 90-KD, ALPHA, CLASS A, MEMBER 1; HSP90AA1","url":"https://www.omim.org/entry/140571"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoli fibrillar center","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Cell Junctions","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/IP6K2"},"hgnc":{"alias_symbol":[],"prev_symbol":["IHPK2"]},"alphafold":{"accession":"Q9UHH9","domains":[{"cath_id":"3.30.470.160","chopping":"16-92_154-338_372-423","consensus_level":"medium","plddt":89.4318,"start":16,"end":423}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UHH9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UHH9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UHH9-F1-predicted_aligned_error_v6.png","plddt_mean":76.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IP6K2","jax_strain_url":"https://www.jax.org/strain/search?query=IP6K2"},"sequence":{"accession":"Q9UHH9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UHH9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UHH9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UHH9"}},"corpus_meta":[{"pmid":"23725456","id":"PMC_23725456","title":"Inositol pyrophosphates: between signalling and metabolism.","date":"2013","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/23725456","citation_count":212,"is_preprint":false},{"pmid":"18033884","id":"PMC_18033884","title":"Requirement of inositol pyrophosphates for full exocytotic capacity in pancreatic beta cells.","date":"2007","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18033884","citation_count":157,"is_preprint":false},{"pmid":"11337497","id":"PMC_11337497","title":"Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11337497","citation_count":138,"is_preprint":false},{"pmid":"21878680","id":"PMC_21878680","title":"Inositol pyrophosphates as mammalian cell signals.","date":"2011","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/21878680","citation_count":136,"is_preprint":false},{"pmid":"24657168","id":"PMC_24657168","title":"Inositol pyrophosphates mediate the DNA-PK/ATM-p53 cell death pathway by regulating CK2 phosphorylation of Tti1/Tel2.","date":"2014","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/24657168","citation_count":105,"is_preprint":false},{"pmid":"31186349","id":"PMC_31186349","title":"The inositol hexakisphosphate kinases IP6K1 and -2 regulate human cellular phosphate homeostasis, including XPR1-mediated phosphate export.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31186349","citation_count":87,"is_preprint":false},{"pmid":"18195352","id":"PMC_18195352","title":"HSP90 regulates cell survival via inositol hexakisphosphate kinase-2.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18195352","citation_count":86,"is_preprint":false},{"pmid":"21078964","id":"PMC_21078964","title":"p53-mediated apoptosis requires inositol hexakisphosphate kinase-2.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21078964","citation_count":83,"is_preprint":false},{"pmid":"25617365","id":"PMC_25617365","title":"Inositol pyrophosphates promote tumor growth and metastasis by antagonizing liver kinase B1.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25617365","citation_count":82,"is_preprint":false},{"pmid":"29078269","id":"PMC_29078269","title":"KO of 5-InsP7 kinase activity transforms the HCT116 colon cancer cell line into a hypermetabolic, growth-inhibited phenotype.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29078269","citation_count":68,"is_preprint":false},{"pmid":"19430495","id":"PMC_19430495","title":"Gene deletion of inositol hexakisphosphate kinase 2 predisposes to aerodigestive tract carcinoma.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19430495","citation_count":61,"is_preprint":false},{"pmid":"24956979","id":"PMC_24956979","title":"IP6K structure and the molecular determinants of catalytic specificity in an inositol phosphate kinase family.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24956979","citation_count":60,"is_preprint":false},{"pmid":"11896621","id":"PMC_11896621","title":"Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11896621","citation_count":58,"is_preprint":false},{"pmid":"21950602","id":"PMC_21950602","title":"Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins.","date":"2011","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/21950602","citation_count":53,"is_preprint":false},{"pmid":"27140681","id":"PMC_27140681","title":"Deletion of inositol hexakisphosphate kinase 1 (IP6K1) reduces cell migration and invasion, conferring protection from aerodigestive tract carcinoma in mice.","date":"2016","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/27140681","citation_count":50,"is_preprint":false},{"pmid":"26245967","id":"PMC_26245967","title":"Inositol Hexakisphosphate Kinase-3 Regulates the Morphology and Synapse Formation of Cerebellar Purkinje Cells via Spectrin/Adducin.","date":"2015","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26245967","citation_count":46,"is_preprint":false},{"pmid":"21262846","id":"PMC_21262846","title":"Casein kinase-2 mediates cell survival through phosphorylation and degradation of inositol hexakisphosphate kinase-2.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21262846","citation_count":43,"is_preprint":false},{"pmid":"15634191","id":"PMC_15634191","title":"Apo2L/TRAIL induction and nuclear translocation of inositol hexakisphosphate kinase 2 during IFN-beta-induced apoptosis in ovarian carcinoma.","date":"2005","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15634191","citation_count":31,"is_preprint":false},{"pmid":"23018034","id":"PMC_23018034","title":"Identification of novel Sp1 targets involved in proliferation and cancer by functional genomics.","date":"2012","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23018034","citation_count":31,"is_preprint":false},{"pmid":"12370820","id":"PMC_12370820","title":"Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12370820","citation_count":29,"is_preprint":false},{"pmid":"20980661","id":"PMC_20980661","title":"Inositol hexakisphosphate kinase-2 acts as an effector of the vertebrate Hedgehog pathway.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20980661","citation_count":24,"is_preprint":false},{"pmid":"35467861","id":"PMC_35467861","title":"Development of Novel IP6K Inhibitors for the Treatment of Obesity and Obesity-Induced Metabolic Dysfunctions.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35467861","citation_count":24,"is_preprint":false},{"pmid":"17379600","id":"PMC_17379600","title":"Effect of inositol hexakisphosphate kinase 2 on transforming growth factor beta-activated kinase 1 and NF-kappaB activation.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17379600","citation_count":21,"is_preprint":false},{"pmid":"36681123","id":"PMC_36681123","title":"Inositol pyrophosphate profiling reveals regulatory roles of IP6K2-dependent enhanced IP7 metabolism in the enteric nervous system.","date":"2023","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36681123","citation_count":20,"is_preprint":false},{"pmid":"22085832","id":"PMC_22085832","title":"Nuclear receptor HNF4α binding sequences are widespread in Alu repeats.","date":"2011","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/22085832","citation_count":19,"is_preprint":false},{"pmid":"32176627","id":"PMC_32176627","title":"LINC00467 knockdown repressed cell proliferation but stimulated cell apoptosis in glioblastoma via miR-339-3p/IP6K2 axis.","date":"2020","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/32176627","citation_count":18,"is_preprint":false},{"pmid":"35353626","id":"PMC_35353626","title":"Inositol hexakisphosphate kinase-2 non-catalytically regulates mitophagy by attenuating PINK1 signaling.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35353626","citation_count":18,"is_preprint":false},{"pmid":"29842835","id":"PMC_29842835","title":"Use of Protein Kinase-Focused Compound Libraries for the Discovery of New Inositol Phosphate Kinase Inhibitors.","date":"2018","source":"SLAS discovery : advancing life sciences R & D","url":"https://pubmed.ncbi.nlm.nih.gov/29842835","citation_count":18,"is_preprint":false},{"pmid":"33547244","id":"PMC_33547244","title":"Inositol hexakisphosphate kinase-2 determines cellular energy dynamics by regulating creatine kinase-B.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33547244","citation_count":17,"is_preprint":false},{"pmid":"31445853","id":"PMC_31445853","title":"Synthesis and characterization of novel isoform-selective IP6K1 inhibitors.","date":"2019","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/31445853","citation_count":17,"is_preprint":false},{"pmid":"30006360","id":"PMC_30006360","title":"Inositol Hexakisphosphate Kinase-2 in Cerebellar Granule Cells Regulates Purkinje Cells and Motor Coordination via Protein 4.1N.","date":"2018","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30006360","citation_count":16,"is_preprint":false},{"pmid":"35156508","id":"PMC_35156508","title":"LINC00467 facilitates the proliferation, migration and invasion of glioma via promoting the expression of inositol hexakisphosphate kinase 2 by binding to miR-339-3p.","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/35156508","citation_count":13,"is_preprint":false},{"pmid":"37804111","id":"PMC_37804111","title":"Machine learning nominates the inositol pathway and novel genes in Parkinson's disease.","date":"2024","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37804111","citation_count":13,"is_preprint":false},{"pmid":"31856847","id":"PMC_31856847","title":"Differential alternative splicing regulation among hepatocellular carcinoma with different risk factors.","date":"2019","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/31856847","citation_count":13,"is_preprint":false},{"pmid":"20872794","id":"PMC_20872794","title":"Screening and identification of differentially expressed genes in goose hepatocytes exposed to free fatty acid.","date":"2010","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20872794","citation_count":12,"is_preprint":false},{"pmid":"34602499","id":"PMC_34602499","title":"Axial Impairment Following Deep Brain Stimulation in Parkinson's Disease: A Surgicogenomic Approach.","date":"2022","source":"Journal of Parkinson's disease","url":"https://pubmed.ncbi.nlm.nih.gov/34602499","citation_count":12,"is_preprint":false},{"pmid":"37270558","id":"PMC_37270558","title":"Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37270558","citation_count":11,"is_preprint":false},{"pmid":"36671538","id":"PMC_36671538","title":"Nucleolar Architecture Is Modulated by a Small Molecule, the Inositol Pyrophosphate 5-InsP7.","date":"2023","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36671538","citation_count":11,"is_preprint":false},{"pmid":"38317282","id":"PMC_38317282","title":"The Ip6k1 and Ip6k2 Kinases Are Critical for Normal Renal Tubular Function.","date":"2024","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/38317282","citation_count":10,"is_preprint":false},{"pmid":"38403246","id":"PMC_38403246","title":"Insights into the roles of inositol hexakisphosphate kinase 1 (IP6K1) in mammalian cellular processes.","date":"2024","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38403246","citation_count":10,"is_preprint":false},{"pmid":"27107179","id":"PMC_27107179","title":"Sequence-based analysis of 5'UTR and coding regions of CASP3 in terms of miRSNPs and SNPs in targetting miRNAs.","date":"2016","source":"Computational biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27107179","citation_count":9,"is_preprint":false},{"pmid":"37013838","id":"PMC_37013838","title":"Synthesis and biological evaluation of flavonoid-based IP6K2 inhibitors.","date":"2023","source":"Journal of enzyme inhibition and medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37013838","citation_count":8,"is_preprint":false},{"pmid":"34589518","id":"PMC_34589518","title":"4.1N-Mediated Interactions and Functions in Nerve System and Cancer.","date":"2021","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/34589518","citation_count":8,"is_preprint":false},{"pmid":"36979316","id":"PMC_36979316","title":"Genetics of Neurogenic Orthostatic Hypotension in Parkinson's Disease, Results from a Cross-Sectional In Silico Study.","date":"2023","source":"Brain sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36979316","citation_count":8,"is_preprint":false},{"pmid":"23591012","id":"PMC_23591012","title":"A kinome-wide siRNA screen identifies multiple roles for protein kinases in hypoxic stress adaptation, including roles for IRAK4 and GAK in protection against apoptosis in VHL-/- renal carcinoma cells, despite activation of the NF-κB pathway.","date":"2013","source":"Journal of biomolecular screening","url":"https://pubmed.ncbi.nlm.nih.gov/23591012","citation_count":7,"is_preprint":false},{"pmid":"31051014","id":"PMC_31051014","title":"PPIP5K1 Suppresses Etoposide-triggered Apoptosis.","date":"2016","source":"Journal of molecular signaling","url":"https://pubmed.ncbi.nlm.nih.gov/31051014","citation_count":7,"is_preprint":false},{"pmid":"40858937","id":"PMC_40858937","title":"Oncometabolite 5-IP7 inhibits inositol 5-phosphatase to license E-cadherin endocytosis.","date":"2025","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/40858937","citation_count":7,"is_preprint":false},{"pmid":"34434651","id":"PMC_34434651","title":"Identification of a circRNA-miRNA-mRNA regulatory network for exploring novel therapeutic options for glioma.","date":"2021","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/34434651","citation_count":7,"is_preprint":false},{"pmid":"33767863","id":"PMC_33767863","title":"IP6K2 predicts favorable clinical outcome of primary breast cancer.","date":"2021","source":"Molecular and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33767863","citation_count":6,"is_preprint":false},{"pmid":"38116421","id":"PMC_38116421","title":"Fragment-Based Screening Identifies New Quinazolinone-Based Inositol Hexakisphosphate Kinase (IP6K) Inhibitors.","date":"2023","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/38116421","citation_count":6,"is_preprint":false},{"pmid":"36817960","id":"PMC_36817960","title":"MAPKAPK2-centric transcriptome profiling reveals its major role in governing molecular crosstalk of IGFBP2, MUC4, and PRKAR2B during HNSCC pathogenesis.","date":"2023","source":"Computational and structural biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/36817960","citation_count":6,"is_preprint":false},{"pmid":"32676038","id":"PMC_32676038","title":"Monitoring Phytate Hydrolysis Using Serial Blood Sampling and Feather Myo-Inositol Levels in Broilers.","date":"2020","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32676038","citation_count":4,"is_preprint":false},{"pmid":"38429095","id":"PMC_38429095","title":"Novel and unusual USP6 fusion partners in aneurysmal bone cyst and their role in pathogenesis and histopathological evaluation of this disease.","date":"2025","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/38429095","citation_count":4,"is_preprint":false},{"pmid":"38980439","id":"PMC_38980439","title":"Circ-IP6K2 suppresses tumor progression by modulating the miR-1292-5p/CAMK2N1 signal in clear cell renal cell carcinoma.","date":"2024","source":"Functional & integrative genomics","url":"https://pubmed.ncbi.nlm.nih.gov/38980439","citation_count":3,"is_preprint":false},{"pmid":"37843983","id":"PMC_37843983","title":"An unconventional gatekeeper mutation sensitizes inositol hexakisphosphate kinases to an allosteric inhibitor.","date":"2023","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/37843983","citation_count":3,"is_preprint":false},{"pmid":"35892236","id":"PMC_35892236","title":"Comparison of Skin Transcriptome between Responder and Non-Responder Vitiligo Lesions to Cell Transplantation: A Clinical Trial Study.","date":"2022","source":"Cell journal","url":"https://pubmed.ncbi.nlm.nih.gov/35892236","citation_count":3,"is_preprint":false},{"pmid":"40075351","id":"PMC_40075351","title":"IP6K2 mutations as a novel mechanism of resistance to oncolytic virus therapy.","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40075351","citation_count":2,"is_preprint":false},{"pmid":"27736936","id":"PMC_27736936","title":"A High-Throughput Screening-Compatible Strategy for the Identification of Inositol Pyrophosphate Kinase Inhibitors.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27736936","citation_count":2,"is_preprint":false},{"pmid":"40879991","id":"PMC_40879991","title":"Knockout Mice as an Experimental Model to Study the Biology of Inositol Pyrophosphates.","date":"2025","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/40879991","citation_count":1,"is_preprint":false},{"pmid":"41249827","id":"PMC_41249827","title":"Integrating machine learning and molecular dynamics simulation to decipher the molecular network of dioxin-associated liposarcoma.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41249827","citation_count":0,"is_preprint":false},{"pmid":"41683831","id":"PMC_41683831","title":"Role of Inositol Hexakisphosphate Kinases in Vascular Smooth Muscle Cell Calcification.","date":"2026","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41683831","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":32276,"output_tokens":5714,"usd":0.091269},"stage2":{"model":"claude-opus-4-6","input_tokens":9252,"output_tokens":4534,"usd":0.239415},"total_usd":0.330684,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"IP6K2 (RID-2) is post-transcriptionally induced by IFN-beta in ovarian carcinoma cells and mediates IFN-beta-induced apoptosis; a mutant IP6K2 with substitutions in the putative inositol phosphate binding domain abrogates IFN-beta-induced apoptosis, establishing its kinase activity as required for this function.\",\n      \"method\": \"Antisense technical knockout, kinase-dead mutant expression, apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with specific phenotypic readout plus mutagenesis of catalytic domain, replicated in multiple follow-up studies\",\n      \"pmids\": [\"11337497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IP6K2 overexpression sensitizes ovarian carcinoma cells to IFN-beta and gamma-irradiation-induced apoptosis by enhancing caspase-8 expression and functioning through DR4/DR5-mediated extrinsic apoptotic pathway; Bcl-2 and dominant-negative DR5 block these effects.\",\n      \"method\": \"Overexpression, colony forming assay, caspase-8 mRNA induction, dominant-negative mutant DR5 and Bcl-2 blocking\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean overexpression with defined pathway placement, single lab\",\n      \"pmids\": [\"11896621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IP6K2 undergoes nuclear translocation after IFN-beta treatment, and this nuclear localization is required for IFN-beta-induced apoptosis; mutations in the NLS of IP6K2 trap the protein in the cytoplasm and confer resistance to IFN-beta-induced cell death.\",\n      \"method\": \"IP6K2-eGFP fusion live imaging, NLS point mutant expression, apoptosis assays\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment with functional consequence via mutagenesis, moderate evidence\",\n      \"pmids\": [\"15634191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"IP6K2 binds TRAF2 via residues Ser-347 and Ser-359, thereby interfering with phosphorylation of TAK1 and inhibiting NF-kappaB signaling; S347A/S359A mutations abolish TRAF2 binding and lead to enhanced TAK1 and NF-kappaB activation following TNF-alpha stimulation.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis, TAK1 phosphorylation assay, NF-kappaB DNA binding assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal interaction with mutagenesis and defined pathway placement\",\n      \"pmids\": [\"17379600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HSP90 physically binds IP6K2 and inhibits its catalytic activity; disruption of this interaction (by HSP90 inhibitory drugs or selective mutations) activates IP6K2 and leads to cell death, identifying HSP90 as a physiological negative regulator of IP6K2.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, mutagenesis, pharmacological HSP90 inhibition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal Co-IP plus in vitro catalytic assay plus mutagenesis in single study\",\n      \"pmids\": [\"18195352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"IP6K2 knockout mice show increased susceptibility to carcinogen-induced oral/esophageal squamous cell carcinoma and paradoxical resistance to ionizing radiation with accelerated DNA repair; direct microinjection of the IP6K2 product 5-PP-Ins(1,2,3,4,6)P5 (but not the substrate IP6) induces cell death, confirming the product mediates apoptosis.\",\n      \"method\": \"Targeted gene knockout mice, carcinogen treatment, comet assay, direct microinjection of inositol pyrophosphate\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — KO mouse with defined phenotypes and direct product injection experiment\",\n      \"pmids\": [\"19430495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"IP6K2 is required for p53-mediated apoptosis: gene disruption of IP6K2 in colorectal cancer cells selectively impairs p53-mediated apoptosis (favoring cell-cycle arrest instead), and IP6K2 binds directly to p53, decreasing expression of pro-arrest targets such as p21.\",\n      \"method\": \"Gene disruption (KO), p53 apoptosis assays, direct co-immunoprecipitation of IP6K2 with p53, p21 expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO with defined apoptosis/arrest phenotype plus direct IP6K2-p53 binding shown by Co-IP\",\n      \"pmids\": [\"21078964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"IP6K2 activity in zebrafish is required for normal craniofacial, somite, and neural crest development and acts as a positive regulator of the Hedgehog signaling pathway downstream of or at the level of Smoothened but upstream of the transcription factor Gli1.\",\n      \"method\": \"Morpholino knockdown in zebrafish, pharmacological IP6K inhibition (TNP), genetic epistasis with smoM2/gli1/ip6k2 overexpression, reversal of cyclopamine inhibition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in zebrafish with multiple rescue/override experiments placing IP6K2 in Hh pathway\",\n      \"pmids\": [\"20980661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Casein kinase-2 (CK2) promotes cell survival by phosphorylating IP6K2 at Ser-347 and Ser-356 within a PEST sequence, leading to IP6K2 ubiquitination and proteasomal degradation; CK2-resistant IP6K2 mutants at these sites are metabolically stable, and cells depleted of IP6K2 are resistant to CK2 inhibitor-induced cell death.\",\n      \"method\": \"In vitro phosphorylation assay, site-directed mutagenesis, ubiquitination assay, metabolic stability assay, CK2 inhibitor treatment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro phosphorylation plus mutagenesis plus ubiquitination assay in single study\",\n      \"pmids\": [\"21262846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IP7 generated by IP6K2 binds CK2 to enhance CK2 phosphorylation of the TTT cochaperone complex (Tel2/Tti1/Tti2), thereby stabilizing DNA-PKcs and ATM, which then phosphorylate p53 at Ser-15 to activate the apoptotic program in cancer cells and murine B cells.\",\n      \"method\": \"In vitro CK2 kinase assay with IP7, binding assays, co-immunoprecipitation, cell-based apoptosis assays with IP6K2 modulation\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstituted biochemical cascade with in vitro kinase assay plus cell-based epistasis, published in high-impact journal\",\n      \"pmids\": [\"24657168\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Crystal structure of an Entamoeba histolytica hybrid IP6K/IP3K was solved and used with molecular modelling and mutagenesis to define the substrate-binding pocket of human IP6K2; two structural elements (an α-helical pair and a 310 helix) form an open clamshell geometry that accommodates InsP6; human IP6K2 retains vestigial IP3K activity.\",\n      \"method\": \"X-ray crystallography, molecular modelling, site-directed mutagenesis, kinase activity assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus mutagenesis and functional assay in single study\",\n      \"pmids\": [\"24956979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IP6K2, via IP7 synthesis, promotes cancer cell migration and tumor metastasis by enhancing cell-matrix adhesion and decreasing cell-cell adhesion; this is mediated by IP7-elicited nuclear sequestration and inactivation of the tumor suppressor LKB1.\",\n      \"method\": \"Cell migration/invasion assays, IP6K2 knockdown, IP7 measurement, subcellular fractionation, LKB1 localization and activity assays, in vivo metastasis mouse model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal assays (cell culture + in vivo) placing IP6K2/IP7 upstream of LKB1 nuclear inactivation\",\n      \"pmids\": [\"25617365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IP6K2 binds protein 4.1N with high affinity and specificity; nuclear translocation of 4.1N is dependent on IP6K2; both proteins are highly expressed in cerebellar granule cells and their interaction regulates Purkinje cell morphology, cerebellar synapses, and locomotor function; disruption of IP6K2-4.1N interaction impairs cell viability.\",\n      \"method\": \"Co-immunoprecipitation, IP6K2 knockout mice, immunofluorescence, synaptic morphology analysis, locomotor behavioral tests\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus KO mouse phenotype plus localization-function link\",\n      \"pmids\": [\"30006360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IP6K1 and IP6K2 together control inositol pyrophosphate (IP7 and IP8) metabolism and thereby regulate phosphate export through the XPR1 phosphate exporter, whose SPX domain is bound by inositol pyrophosphates; double KO of IP6K1/2 in HCT116 cells elevates intracellular phosphate and alters phosphate flux.\",\n      \"method\": \"CRISPR knockout of IP6K1/2, PAGE and HPLC inositol phosphate profiling, nucleotide analysis, Malachite green phosphate assay, [32Pi] pulse labeling, XPR1 SPX domain binding assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic KO plus multiple biochemical assays demonstrating IP7/IP8 depletion and XPR1 binding\",\n      \"pmids\": [\"31186349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IP6K2 associates with creatine kinase-B (CK-B) in mouse brain; IP6K2-KO cerebella show reduced phosphocreatine and ATP, increased reactive oxygen species, increased protein oxidative damage, and impaired cytochrome-c1 (complex III) expression, establishing IP6K2-CK-B interaction as a regulator of energy homeostasis and neuroprotection.\",\n      \"method\": \"Proteomic interactome (IP6K2 pull-down/MS), co-immunoprecipitation, metabolite assays (phosphocreatine, ATP, ROS), IP6K2 knockout mice, rescue with N-acetylcysteine and phosphocreatine\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — MS-identified binding partner confirmed by Co-IP, KO phenotype with biochemical readouts and partial rescue\",\n      \"pmids\": [\"33547244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IP6K2 attenuates PINK1-mediated mitophagy in the brain through a catalytically independent mechanism; overexpression of both wild-type and kinase-dead IP6K2 reverses mitophagy markers in knockdown cells; the mitoprotective effect of IP6K2 depends on PINK1, as IP6K2 supplementation fails to reverse LC3-II in IP6K2-PINK1 double-knockdown cells.\",\n      \"method\": \"IP6K2 knockdown, kinase-dead mutant overexpression, PINK1 double knockdown, Western blot for mitophagy/mitochondrial markers (Drp-1, PGC1-α, NRF-1, LC3-II)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — kinase-dead mutant distinguishes catalytic vs. non-catalytic function; epistasis with PINK1 double-KD\",\n      \"pmids\": [\"35353626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IP6K2-generated 5-IP7 modulates nucleolar granular region architecture: overexpression of wild-type (but not kinase-dead) IP6K2 expands the outer nucleolar granular region, while IP6K1+IP6K2 siRNA knockdown or pan-IP6K inhibition shrinks it back; proposed mechanism is electrostatic bridging of positively charged nucleolar protein surfaces.\",\n      \"method\": \"Quantitative confocal imaging, CRISPR-KO (NUDT3, PPIP5Ks), wild-type vs. kinase-dead IP6K2 expression, siRNA knockdown, pan-IP6K inhibitor\",\n      \"journal\": \"Biomolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct imaging with kinase-dead control, single lab, mechanistic model proposed but not biochemically reconstituted\",\n      \"pmids\": [\"36671538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IP6K2 expression in enteric neurons drives high IP7 synthesis in the gastrointestinal tract; IP6K2-knockout mice show significantly impaired IP7 metabolism in the gut, and transcriptome analysis of duodenal muscularis externa indicates the IP6K2-IP7 axis regulates genes associated with neuronal differentiation, maturation, and function of the enteric nervous system.\",\n      \"method\": \"LC-MS inositol pyrophosphate profiling, IP6K2-KO mice, tissue fractionation, whole transcriptome analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with LC-MS quantification and transcriptome, but downstream mechanism not fully reconstituted\",\n      \"pmids\": [\"36681123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"IP6K2-generated 5-IP7 promotes E-cadherin endocytosis in colorectal cancer by inhibiting inositol 5-phosphatases (e.g., OCRL), thereby elevating PI(4,5)P2 levels at adherens junctions and recruiting endocytic adaptors; IP6K2 is activated via a ROS-Src phosphorylation axis; intestinal epithelium-specific IP6K2 deletion attenuates DSS-induced colitis/CRC.\",\n      \"method\": \"In vitro kinase assay, Co-IP, PI(4,5)P2 measurement, endocytosis assays, OCRL binding-deficient mutant, IP6K2 conditional KO mice, DSS colitis model, IP6K2-selective inhibitor\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical assays (kinase assay, PI(4,5)P2 measurement, binding mutant, KO mouse, selective inhibitor) establishing mechanistic cascade\",\n      \"pmids\": [\"40858937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"IP6K2 (together with IP6K1) is required for synthesis of renal 5-IP7 and for normal expression and function of proximal tubule Na+/Pi cotransporters NaPi-IIa and NaPi-IIc; renal tubule-specific Ip6k1/2-KO mice develop hypophosphatemia, reduced FGF23, increased bone resorption, diuresis, albuminuria, and hypercalciuria.\",\n      \"method\": \"Renal cell line (opossum kidney) IP6K knockdown, renal tubular-specific Ip6k1/2-KO mice, phosphate transport assays, brush border membrane vesicle uptake, plasma metabolite measurements\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO mouse with multiple biochemical and physiological phenotypic readouts\",\n      \"pmids\": [\"38317282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A gatekeeper mutation in IP6K2 (valine substitution) sensitizes it to an allosteric inhibitor (FMP-201300) that binds an allosteric pocket adjacent to the ATP-binding site by displacing the αC helix; hydrogen-deuterium exchange mass spectrometry confirmed the allosteric mechanism.\",\n      \"method\": \"Analog-sensitive kinase approach, high-throughput screen, HDX-MS, biochemical kinase inhibition assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — HDX-MS structural evidence plus biochemical validation, single study\",\n      \"pmids\": [\"37843983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"IP6K2 silencing in calcifying vascular smooth muscle cells (VSMCs) ameliorates phosphate-induced pro-calcific marker expression and VSMC calcification; mechanistically, IP6K2-produced 5-IP7 inhibits AKT signaling, and AKT inhibition abolishes the protective effects of IP6K2 knockdown while SGK1 inhibition restores them, suggesting an IP6K2/5-IP7-AKT/SGK1 signaling axis in calcification.\",\n      \"method\": \"IP6K2 siRNA knockdown in primary human aortic VSMCs, calcification assays, AKT phosphorylation Western blot, AKT and SGK1 inhibitors\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with pharmacological rescue placing IP6K2 upstream of AKT/SGK1, single lab\",\n      \"pmids\": [\"41683831\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IP6K2 is an inositol hexakisphosphate kinase that generates the inositol pyrophosphate 5-IP7 (diphosphoinositol pentakisphosphate); it promotes apoptosis by directly binding p53 and modulating its transcriptional output, activates CK2-mediated phosphorylation of the TTT cochaperone complex to stabilize DNA-PKcs/ATM and drive p53 Ser-15 phosphorylation, inhibits NF-κB signaling by binding TRAF2 and blocking TAK1 phosphorylation, undergoes IFN-beta-induced nuclear translocation required for apoptosis, is kept in check by HSP90 binding (which inhibits its catalytic activity) and by CK2-mediated PEST-site phosphorylation that targets it for ubiquitin-proteasomal degradation; 5-IP7 also acts as a positive effector of Hedgehog signaling (downstream of Smoothened, upstream of Gli1), promotes LKB1 nuclear inactivation to drive tumor metastasis, inhibits OCRL phosphatase at adherens junctions to elevate PI(4,5)P2 and license E-cadherin endocytosis, and regulates phosphate homeostasis (via XPR1 and renal NaPi-IIa/IIc), mitochondrial energy dynamics through CK-B interaction, and PINK1-dependent mitophagy through a non-catalytic mechanism.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"IP6K2 is an inositol hexakisphosphate kinase that generates 5-PP-InsP5 (5-IP7), a signaling pyrophosphate that controls cell-fate decisions spanning apoptosis, proliferation, phosphate homeostasis, and tissue morphogenesis. IP6K2 promotes apoptosis through multiple convergent mechanisms: its product 5-IP7 activates CK2-dependent phosphorylation of the TTT cochaperone complex to stabilize DNA-PKcs/ATM and drive p53 Ser-15 phosphorylation [PMID:24657168]; IP6K2 directly binds p53 to shift transcriptional output from cell-cycle arrest toward apoptosis [PMID:21078964]; and it inhibits NF-κB survival signaling by binding TRAF2 and blocking TAK1 phosphorylation [PMID:17379600]. Beyond apoptosis, IP6K2 acts as a positive regulator of Hedgehog signaling downstream of Smoothened [PMID:20980661], controls phosphate export via XPR1 and renal NaPi-IIa/IIc cotransporter expression [PMID:31186349, PMID:38317282], promotes E-cadherin endocytosis by inhibiting OCRL to elevate PI(4,5)P2 at adherens junctions [PMID:40858937], and regulates mitochondrial energy homeostasis through its interaction with creatine kinase-B and a catalytically independent attenuation of PINK1-mediated mitophagy [PMID:33547244, PMID:35353626].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing IP6K2 as a pro-apoptotic kinase answered whether inositol pyrophosphate metabolism was linked to programmed cell death: IFN-β post-transcriptionally induces IP6K2, and its catalytic activity is required for IFN-β-induced apoptosis.\",\n      \"evidence\": \"Antisense knockdown and kinase-dead mutant expression in ovarian carcinoma cells with apoptosis readouts\",\n      \"pmids\": [\"11337497\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream mediators of IP6K2-driven apoptosis were unknown\", \"Whether 5-IP7 itself or another product mediated the effect was unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identifying the extrinsic death receptor pathway as a downstream effector placed IP6K2 upstream of DR4/DR5 and caspase-8 in apoptosis signaling.\",\n      \"evidence\": \"Overexpression in ovarian carcinoma cells; blocking by dominant-negative DR5 and Bcl-2\",\n      \"pmids\": [\"11896621\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reliance on overexpression without loss-of-function confirmation\", \"Whether endogenous IP6K2 levels are sufficient to engage DR4/DR5 was untested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating IFN-β-induced nuclear translocation of IP6K2 and its requirement for apoptosis resolved where in the cell IP6K2 must act to execute its death-promoting function.\",\n      \"evidence\": \"IP6K2-eGFP fusion imaging and NLS point mutant expression in apoptosis assays\",\n      \"pmids\": [\"15634191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nuclear substrates or binding partners mediating apoptosis were unidentified\", \"Whether catalysis occurs in the nucleus or whether nuclear localization serves a scaffolding role was unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Discovery that IP6K2 binds TRAF2 and inhibits TAK1/NF-κB signaling revealed a second mechanism through which IP6K2 shifts cell fate toward apoptosis — by suppressing pro-survival NF-κB.\",\n      \"evidence\": \"Co-immunoprecipitation, S347A/S359A mutagenesis, TAK1 phosphorylation and NF-κB DNA binding assays\",\n      \"pmids\": [\"17379600\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this requires catalytic activity or is a scaffolding function was not dissected\", \"In vivo relevance of the TRAF2 interaction was not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identifying HSP90 as a physical inhibitor of IP6K2 catalytic activity established a tonic brake on IP6K2 and explained how HSP90 inhibitors trigger cell death — by unleashing IP6K2.\",\n      \"evidence\": \"Reciprocal Co-IP, in vitro kinase assay, HSP90 inhibitor treatment, mutagenesis\",\n      \"pmids\": [\"18195352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HSP90 regulates IP6K2 stability in addition to activity was unresolved\", \"Structural basis of HSP90-IP6K2 interaction was unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"IP6K2 knockout mice provided in vivo confirmation that IP6K2 is a tumor suppressor: KO animals show increased carcinogen susceptibility, and direct microinjection of 5-IP7 induces cell death, proving the product — not the enzyme per se — mediates apoptosis.\",\n      \"evidence\": \"IP6K2 knockout mice, carcinogen-induced tumor model, microinjection of 5-PP-InsP5\",\n      \"pmids\": [\"19430495\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The paradoxical radiation resistance and accelerated DNA repair in KO mice remained mechanistically unexplained\", \"Whether compensatory IP6K1/3 activity confounds phenotypes was not addressed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Two advances linked IP6K2 to specific signaling pathways: direct binding to p53 shifts its transcriptional output from arrest to apoptosis, and genetic epistasis in zebrafish placed IP6K2 downstream of Smoothened in Hedgehog signaling.\",\n      \"evidence\": \"IP6K2 KO in HCT116 cells with p53 apoptosis/arrest readouts and Co-IP (p53); morpholino knockdown in zebrafish with Hh pathway epistasis (Hedgehog)\",\n      \"pmids\": [\"21078964\", \"20980661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How IP6K2 binding alters p53 target gene selectivity at the chromatin level was unknown\", \"The Hedgehog mechanism lacked identification of a direct IP6K2/IP7 target between Smoothened and Gli1\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"CK2-mediated phosphorylation of IP6K2 PEST residues triggers its ubiquitination and proteasomal degradation, revealing a feedback loop: CK2 activity promotes survival by eliminating the pro-apoptotic kinase.\",\n      \"evidence\": \"In vitro CK2 phosphorylation, mutagenesis of Ser-347/Ser-356, ubiquitination assay, metabolic stability\",\n      \"pmids\": [\"21262846\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The specific E3 ubiquitin ligase was not identified\", \"Whether CK2-mediated degradation is stimulus-regulated was untested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Reconstitution of a 5-IP7→CK2→TTT→DNA-PKcs/ATM→p53-Ser15 cascade provided the first complete biochemical pathway from IP6K2 catalytic product to p53 activation, while structural analysis revealed the substrate-binding clamshell geometry of the IP6K family.\",\n      \"evidence\": \"In vitro CK2 kinase assay with IP7, Co-IP, cell-based epistasis (signaling cascade); X-ray crystallography of Entamoeba IP6K, human IP6K2 modeling and mutagenesis (structure)\",\n      \"pmids\": [\"24657168\", \"24956979\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"A high-resolution structure of human IP6K2 itself was still lacking\", \"Whether CK2 activation by IP7 is selective to IP6K2-derived pools vs. IP6K1-derived pools was not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that IP6K2/IP7 promotes tumor metastasis via nuclear sequestration and inactivation of LKB1 revealed a pro-tumorigenic face of IP6K2, contrasting its well-established tumor-suppressive apoptotic role.\",\n      \"evidence\": \"Cell migration/invasion assays, IP6K2 knockdown, LKB1 localization, in vivo metastasis model\",\n      \"pmids\": [\"25617365\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How 5-IP7 mechanistically drives LKB1 nuclear sequestration was not biochemically defined\", \"Context-dependent switching between tumor-suppressive and pro-metastatic roles was unexplained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identification of protein 4.1N as a high-affinity IP6K2 partner linked IP6K2 to cerebellar function: IP6K2 controls 4.1N nuclear translocation, and their interaction regulates Purkinje cell morphology and locomotor behavior.\",\n      \"evidence\": \"Reciprocal Co-IP, IP6K2 KO mice, cerebellar immunofluorescence, locomotor behavioral tests\",\n      \"pmids\": [\"30006360\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the 4.1N interaction requires IP6K2 catalytic activity was not tested\", \"Downstream nuclear targets of 4.1N were unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating that IP6K1/2-generated inositol pyrophosphates bind the SPX domain of XPR1 and control phosphate export established IP6K2 as a regulator of cellular phosphate homeostasis.\",\n      \"evidence\": \"CRISPR double KO of IP6K1/2 in HCT116, HPLC/PAGE IP7/IP8 profiling, 32Pi flux, SPX domain binding assay\",\n      \"pmids\": [\"31186349\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual contributions of IP6K1 vs. IP6K2 to XPR1 regulation were not separated\", \"In vivo phosphate phenotypes of IP6K2-single KO were not reported in this study\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovery that IP6K2 associates with creatine kinase-B and that IP6K2 KO cerebella show depleted phosphocreatine/ATP and elevated ROS established a bioenergetic function for IP6K2 in neuroprotection.\",\n      \"evidence\": \"Proteomic pull-down/MS, Co-IP, metabolite quantification, IP6K2 KO mice, rescue with N-acetylcysteine and phosphocreatine\",\n      \"pmids\": [\"33547244\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IP6K2 enzymatic activity or a scaffolding role underlies the CK-B interaction was unresolved\", \"Mechanism linking IP6K2-CK-B to cytochrome c1/complex III expression was unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating that both wild-type and kinase-dead IP6K2 attenuate PINK1-dependent mitophagy in a PINK1-epistatic manner uncovered a catalytically independent, non-canonical function of IP6K2 in mitochondrial quality control.\",\n      \"evidence\": \"IP6K2 knockdown and kinase-dead rescue, PINK1 double-KD epistasis, mitophagy marker Western blots\",\n      \"pmids\": [\"35353626\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical interaction between IP6K2 and PINK1 was not shown\", \"Whether the non-catalytic mechanism involves a scaffolding surface or protein-protein interaction domain was undetermined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Multiple studies expanded IP6K2's tissue-specific roles: IP6K2 is the dominant IP7 source in enteric neurons and regulates enteric nervous system gene programs; IP6K2-derived IP7 modulates nucleolar granular region architecture; and an allosteric inhibitor pocket was mapped by HDX-MS.\",\n      \"evidence\": \"IP6K2-KO mice with gut LC-MS IP7 profiling and transcriptomics (enteric); confocal imaging with WT vs. kinase-dead IP6K2 (nucleolus); analog-sensitive kinase screen with HDX-MS (allosteric pocket)\",\n      \"pmids\": [\"36681123\", \"36671538\", \"37843983\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enteric neuron phenotypes were transcriptomic without functional neuronal assays\", \"Nucleolar mechanism proposed as electrostatic bridging but not biochemically reconstituted\", \"Allosteric inhibitor tested only on gatekeeper mutant, not wild-type IP6K2\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Renal tubular-specific IP6K1/2 knockout revealed that IP6K2-derived 5-IP7 is essential for NaPi-IIa/IIc expression and renal phosphate reabsorption, with KO mice developing hypophosphatemia and secondary bone/mineral phenotypes.\",\n      \"evidence\": \"Conditional renal tubular Ip6k1/2-KO mice, brush border membrane vesicle phosphate uptake, plasma metabolite measurements\",\n      \"pmids\": [\"38317282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual contribution of IP6K2 vs. IP6K1 in the renal tubule was not dissected\", \"Mechanism by which 5-IP7 regulates NaPi-IIa/IIc expression (transcriptional vs. post-translational) was not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A ROS→Src→IP6K2→5-IP7⊣OCRL→PI(4,5)P2→E-cadherin endocytosis axis was delineated in colorectal cancer, and intestinal epithelium-specific IP6K2 deletion attenuated colitis-associated carcinogenesis, establishing IP6K2 as a druggable node in junction remodeling.\",\n      \"evidence\": \"In vitro kinase assay, OCRL binding-deficient mutant, PI(4,5)P2 measurement, conditional KO mice in DSS colitis model, IP6K2-selective inhibitor\",\n      \"pmids\": [\"40858937\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether OCRL inhibition by 5-IP7 is direct or mediated by an intermediate was not fully resolved\", \"Specificity of the IP6K2-selective inhibitor in vivo was not comprehensively profiled\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the high-resolution structure of human IP6K2, how IP6K2 switches between tumor-suppressive and pro-metastatic outputs in different cellular contexts, the identity of the E3 ligase mediating CK2-dependent IP6K2 degradation, and how IP6K2's catalytic and non-catalytic functions are coordinately regulated.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No crystal structure of full-length human IP6K2\", \"E3 ubiquitin ligase for IP6K2 degradation unidentified\", \"Context-dependent switch between pro-apoptotic and pro-metastatic roles is mechanistically unexplained\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 5, 9, 10, 13, 18]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 6, 15, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 12, 16]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 4]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 1, 5, 6, 9]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 7, 9, 11, 21]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [13, 14, 19]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [13, 19]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TP53\",\n      \"TRAF2\",\n      \"HSP90\",\n      \"EPB41L1\",\n      \"CKB\",\n      \"CSNK2A1\",\n      \"OCRL\",\n      \"PINK1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}